Lantheus Medical Imaging
- Thread starter Anonymous
- Start date
-
- Tags
- None
Lantheus appears to be a bit selective of the s*** storms it creates. Word on the street, Eric Guilbert went to work for Jubliant. No s*** storm by Lantheus. Word on the street, Mark Hibbert went to work for GE. No s*** storm by Lantheus. Word on the street, Stacey Brown went to work for GE. Lantheus causes a large s*** storm.
Roll the dice. Pick your poison. Try your luck. What's the price of admission for this ride?
Roll the dice. Pick your poison. Try your luck. What's the price of admission for this ride?
Stacey Brown went to work for GE. Lantheus causes a large s*** storm...But she gets hired anyway!
Here's what you have to understand.
If you didn't sign a noncompete at time of hire, then you can go wherever you want and they can't say shit. When I resigned, they actually tried to get me to sign a noncompete, which I declined to do. I am free and clear and can work where I like. They actually tried to tell me that I had to sign it. I asked them what would happen if I refused, and they had no answer.
When one is laid off, they will ask you to sign a noncompete as a condition of the severance. You don't have to sign it, but if you refuse, then they won't give you the severance (along with the noncompete you will also be asked to sign something that you won't sue them). This is legal.
The real issue (ethically, NOT legally) is that they put these noncompetes on even low level employees. People who don't have access to any sensitive information. In that way it seems spiteful and petty.
...include vindictive and self serving to the list. The place is run by control freaks that get off by screwing you over in as many ways as possible. They make examples of some as a means to control and create fear among the many. It's a miserable culture and environment to be trapped in.
Read it and weep Lantheus.........http://www.biospace.com/news_story.aspx?StoryID=414218&full=1....looky, looky, looky
Thank God for all those non-compete stipulations........otherwise you would go deaf at the sound of thundering feet as the rats left the sinking ship!!!!
I retired 5-1/2 years ago. The place seemed to me it would have failed in the next couple of years. Never thought that craphole would be in business this long. Go Phoenix!
Money is money, no matter how it's made. That's the Lantheus and Avista way. As long as they can finagle the books, even if takes changing CFO's like underwear, stay one step ahead of creditors and dumb ass investors, they'll keep on rolling along. The days of the company making hundreds of millions of dollars a year are long gone. Profits will continue to go down, employees will continue to be layed off, disrespected, abused and some overworked...whatever it takes to continue to squeeze out a buck.
Started with NEN in 1978, what a glorious company that was. Even through it's many iterations, up to but not including BMS, what a fabulous place to work it was! Employees were highly though of, taken care of, and valued. AAHH, for the good old days! Glad I was there to see what a great company it was.
You want to know where the money goes today, just look at the new CFO's salary and layoff package. Anyone out there get this deal when they got let go?
In connection with Mr. Crowley's appointment as Chief Financial Officer and Treasurer, the annual base salary payable under his existing employment agreement was increased to $360,000, effective as of March 25, 2016, and the target amount of his annual bonus award payable under his existing employment agreement was increased to 50% of his new base salary.
Mr. Crowley's amended employment agreement also provides the following severance benefits. In the event of a termination by the Company without cause, he will be entitled to an amount equal to the sum of (i) his base salary on the date of termination and (ii) a pro rata portion (based upon the percentage of the fiscal year that elapsed through the date of his termination) of 50% of his base salary on the date of termination, payable in substantially equal installments over a period of 12 months, and certain benefit subsidies for a period of 12 months. In the event of a termination by the Company without cause or by him for good reason within 12 months following a change of control, he will be entitled to an amount equal to 150% of his base salary on the date of termination, payable in substantially equal installments over a period of 12 months, and 12 months of certain benefit subsidies.
In connection with Mr. Crowley's appointment as Chief Financial Officer and Treasurer, the annual base salary payable under his existing employment agreement was increased to $360,000, effective as of March 25, 2016, and the target amount of his annual bonus award payable under his existing employment agreement was increased to 50% of his new base salary.
Mr. Crowley's amended employment agreement also provides the following severance benefits. In the event of a termination by the Company without cause, he will be entitled to an amount equal to the sum of (i) his base salary on the date of termination and (ii) a pro rata portion (based upon the percentage of the fiscal year that elapsed through the date of his termination) of 50% of his base salary on the date of termination, payable in substantially equal installments over a period of 12 months, and certain benefit subsidies for a period of 12 months. In the event of a termination by the Company without cause or by him for good reason within 12 months following a change of control, he will be entitled to an amount equal to 150% of his base salary on the date of termination, payable in substantially equal installments over a period of 12 months, and 12 months of certain benefit subsidies.
It is because Guilbert, a nice guy won't hurt business. Hibbert is such a pompous ass he is harmless. Everyone at LMI knows he will spend most of the time stroking his beard telling GE how wonderful he is....in other words harmless....Brown? Obviously someone LMI thinks can hurt them.....it's that simple
Guilbert. I never met a more serious, cheap, incompetent moron in my life. Only in Canada would someone with such an intellectual deficit not be given a set of antlers and dropped into the Canadian wilderness naked during hunting season. He fucked over and under paid everyone who's ever had the misfortune of working for him. Him and his boss, "The Joker".
A pair to beat a full house if there ever was one.
A typical Lantheus sales rep counting their precious vials. My vials! My precious vials!
OXFORD, England & BURLINGTON, Mass.--(BUSINESS WIRE)--Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced that it has established operations in the United States at 25 Burlington Mall Road, Suite 404, in Burlington, Mass. Blue Earth Diagnostics is dedicated to developing and commercializing innovative PET imaging products that address unmet needs in cancer. The Company also announced the creation of key appointments for Blue Earth Diagnostics Inc.: Michael W. Heslop, as President; Peter Gardiner, MB ChB, MRCP, FFPM, as Vice President, Medical Affairs; Bradley K. Pounds as Vice President, Sales, U.S.; David Pendleton, Vice President, Marketing; Christa Dhimo, Vice President, Strategy & Execution U.S.; and Priscilla Harlan, Vice President, Corporate Communications. Blue Earth Diagnostics Inc. is a wholly-owned subsidiary of U.K.-based Blue Earth Diagnostics Ltd.
“We are very pleased to be in Massachusetts and we look forward to being an active and productive member of the Burlington and Massachusetts business communities.”
Tweet this
“A strong presence in the United States is a critical next step in Blue Earth’s mission to deliver new molecular imaging agents to cancer patients with unmet medical needs,” said Jonathan Allis, D.Phil., CEO of Blue Earth Diagnostics Ltd. “With our lead PET imaging product candidate, fluciclovine F 18, in Priority Review with the U.S. Food and Drug Administration, we need to plan for its potential approval and for future growth. Mike Heslop has been leading the U.S. team as President of Blue Earth Diagnostics Inc. With his leadership and that of the other proven industry leaders who have recently joined the Company, we believe we are well-positioned for success and we are excited about the future.”
“Blue Earth’s headquarters in Massachusetts will provide sales, marketing and medical affairs support for the development and commercialization of fluciclovine F 18 in the important U.S. market,” said Michael W. Heslop, President of Blue Earth Diagnostics Inc. “We are very pleased to be in Massachusetts and we look forward to being an active and productive member of the Burlington and Massachusetts business communities.”
Michael W. Heslop, President, Blue Earth Diagnostics Inc.
Mr. Heslop is the President of Blue Earth Diagnostics Inc. and has more than 25 years of experience in commercial and general management with Glaxo Wellcome USA, Genzyme Corporation and, most recently, Lantheus Medical Imaging, where he was Vice President Business Development and Strategy. While at Genzyme, he held the positions of Senior Vice President & General Manager of the Biosurgery and Endocrine businesses, and Vice President, Global Marketing, PGH Business. Mr. Heslop received a B.Sc. degree in Biology from McGill University and an M.B.A. from Concordia University.
Peter Gardiner, MB ChB, MRCP, FFPM, Vice President, Medical Affairs
Dr. Gardiner is responsible for the medical and scientific support of all commercial activities in the United States. His more than 30 years of industry experience has included clinical research and medical affairs roles of increasing responsibility with GD Searle, Gensia, DuPont Pharmaceuticals, Bristol-Myers Squibb, BG Medicine and Navidea Biopharmaceuticals. A graduate of Leeds University Medical School, Dr. Gardiner is a Member of the Royal College of Physicians and a Fellow of its Faculty of Pharmaceutical Medicine.
Bradley K. Pounds, Vice President, Sales U.S.
Mr. Pounds has more than 30 years of experience in diagnostic imaging, including radiopharmaceuticals and contrast agents used for ultrasound and magnetic resonance imaging. He has led multifunctional teams in marketing, medical affairs and sales for both large and small pharmaceutical companies, including Lantheus Medical Imaging, Lilly USA and Navidea Biopharmaceuticals. Mr. Pounds has a Bachelor of Science degree from the University of Houston.
David Pendleton, Vice President, Marketing
Mr. Pendleton has more than 30 years of experience in diagnostic imaging and radiopharmaceuticals and has held numerous commercial leadership positions in marketing, sales and business development, including executive positions at New England Nuclear, DuPont Medical Imaging, Bristol-Myers Squibb, Theseus Imaging, inVentiv Health, Lantheus Medical Imaging and Navidea Biopharmaceuticals. He has consulted for a variety of companies across numerous therapeutic specialties. Mr. Pendleton has a Bachelor of Science degree from Northeastern University.
Christa Dhimo, Vice President, Strategy & Execution U.S.
Ms. Dhimo has more than 20 years of experience in setting and executing global growth and performance strategies. She has led many initiatives across various industries in companies both large and small such as Fidelity Investments, Salary.com (an IBM Company), Raytheon, and, most recently, Lantheus Medical Imaging where she was the Senior Director of Strategic Programs. Ms. Dhimo is a PMP® and received a BA from the University of Massachusetts, an MBA from Northeastern University and a Master in Management - Informatics from the University of Dallas. She also holds a Master Certificate in Strategic Organizational Leadership from Villanova University.
Priscilla Harlan, Vice President, Corporate Communications
Ms. Harlan has more than 25 years of communications experience in the life sciences industry, including executive positions at Lantheus Medical Imaging, Molecular Insight Pharmaceuticals and Sepracor (now Sunovion) and agency leadership positions at Feinstein Kean Healthcare (Ogilvy) and Complete Healthcare Communications. She has consulted to companies across a spectrum of therapeutic areas. Ms. Harlan has a Bachelor of Arts degree in Biology and History from the University of North Carolina.
“We are very pleased to be in Massachusetts and we look forward to being an active and productive member of the Burlington and Massachusetts business communities.”
Tweet this
“A strong presence in the United States is a critical next step in Blue Earth’s mission to deliver new molecular imaging agents to cancer patients with unmet medical needs,” said Jonathan Allis, D.Phil., CEO of Blue Earth Diagnostics Ltd. “With our lead PET imaging product candidate, fluciclovine F 18, in Priority Review with the U.S. Food and Drug Administration, we need to plan for its potential approval and for future growth. Mike Heslop has been leading the U.S. team as President of Blue Earth Diagnostics Inc. With his leadership and that of the other proven industry leaders who have recently joined the Company, we believe we are well-positioned for success and we are excited about the future.”
“Blue Earth’s headquarters in Massachusetts will provide sales, marketing and medical affairs support for the development and commercialization of fluciclovine F 18 in the important U.S. market,” said Michael W. Heslop, President of Blue Earth Diagnostics Inc. “We are very pleased to be in Massachusetts and we look forward to being an active and productive member of the Burlington and Massachusetts business communities.”
Michael W. Heslop, President, Blue Earth Diagnostics Inc.
Mr. Heslop is the President of Blue Earth Diagnostics Inc. and has more than 25 years of experience in commercial and general management with Glaxo Wellcome USA, Genzyme Corporation and, most recently, Lantheus Medical Imaging, where he was Vice President Business Development and Strategy. While at Genzyme, he held the positions of Senior Vice President & General Manager of the Biosurgery and Endocrine businesses, and Vice President, Global Marketing, PGH Business. Mr. Heslop received a B.Sc. degree in Biology from McGill University and an M.B.A. from Concordia University.
Peter Gardiner, MB ChB, MRCP, FFPM, Vice President, Medical Affairs
Dr. Gardiner is responsible for the medical and scientific support of all commercial activities in the United States. His more than 30 years of industry experience has included clinical research and medical affairs roles of increasing responsibility with GD Searle, Gensia, DuPont Pharmaceuticals, Bristol-Myers Squibb, BG Medicine and Navidea Biopharmaceuticals. A graduate of Leeds University Medical School, Dr. Gardiner is a Member of the Royal College of Physicians and a Fellow of its Faculty of Pharmaceutical Medicine.
Bradley K. Pounds, Vice President, Sales U.S.
Mr. Pounds has more than 30 years of experience in diagnostic imaging, including radiopharmaceuticals and contrast agents used for ultrasound and magnetic resonance imaging. He has led multifunctional teams in marketing, medical affairs and sales for both large and small pharmaceutical companies, including Lantheus Medical Imaging, Lilly USA and Navidea Biopharmaceuticals. Mr. Pounds has a Bachelor of Science degree from the University of Houston.
David Pendleton, Vice President, Marketing
Mr. Pendleton has more than 30 years of experience in diagnostic imaging and radiopharmaceuticals and has held numerous commercial leadership positions in marketing, sales and business development, including executive positions at New England Nuclear, DuPont Medical Imaging, Bristol-Myers Squibb, Theseus Imaging, inVentiv Health, Lantheus Medical Imaging and Navidea Biopharmaceuticals. He has consulted for a variety of companies across numerous therapeutic specialties. Mr. Pendleton has a Bachelor of Science degree from Northeastern University.
Christa Dhimo, Vice President, Strategy & Execution U.S.
Ms. Dhimo has more than 20 years of experience in setting and executing global growth and performance strategies. She has led many initiatives across various industries in companies both large and small such as Fidelity Investments, Salary.com (an IBM Company), Raytheon, and, most recently, Lantheus Medical Imaging where she was the Senior Director of Strategic Programs. Ms. Dhimo is a PMP® and received a BA from the University of Massachusetts, an MBA from Northeastern University and a Master in Management - Informatics from the University of Dallas. She also holds a Master Certificate in Strategic Organizational Leadership from Villanova University.
Priscilla Harlan, Vice President, Corporate Communications
Ms. Harlan has more than 25 years of communications experience in the life sciences industry, including executive positions at Lantheus Medical Imaging, Molecular Insight Pharmaceuticals and Sepracor (now Sunovion) and agency leadership positions at Feinstein Kean Healthcare (Ogilvy) and Complete Healthcare Communications. She has consulted to companies across a spectrum of therapeutic areas. Ms. Harlan has a Bachelor of Arts degree in Biology and History from the University of North Carolina.
OXFORD, England & BURLINGTON, Mass.--(BUSINESS WIRE)--Blue Earth Diagnostics, a molecular imaging diagnostics company, today announced that it has established operations in the United States at 25 Burlington Mall Road, Suite 404, in Burlington, Mass. Blue Earth Diagnostics is dedicated to developing and commercializing innovative PET imaging products that address unmet needs in cancer. The Company also announced the creation of key appointments for Blue Earth Diagnostics Inc.: Michael W. Heslop, as President; Peter Gardiner, MB ChB, MRCP, FFPM, as Vice President, Medical Affairs; Bradley K. Pounds as Vice President, Sales, U.S.; David Pendleton, Vice President, Marketing; Christa Dhimo, Vice President, Strategy & Execution U.S.; and Priscilla Harlan, Vice President, Corporate Communications. Blue Earth Diagnostics Inc. is a wholly-owned subsidiary of U.K.-based Blue Earth Diagnostics Ltd.
“We are very pleased to be in Massachusetts and we look forward to being an active and productive member of the Burlington and Massachusetts business communities.”
Tweet this
“A strong presence in the United States is a critical next step in Blue Earth’s mission to deliver new molecular imaging agents to cancer patients with unmet medical needs,” said Jonathan Allis, D.Phil., CEO of Blue Earth Diagnostics Ltd. “With our lead PET imaging product candidate, fluciclovine F 18, in Priority Review with the U.S. Food and Drug Administration, we need to plan for its potential approval and for future growth. Mike Heslop has been leading the U.S. team as President of Blue Earth Diagnostics Inc. With his leadership and that of the other proven industry leaders who have recently joined the Company, we believe we are well-positioned for success and we are excited about the future.”
“Blue Earth’s headquarters in Massachusetts will provide sales, marketing and medical affairs support for the development and commercialization of fluciclovine F 18 in the important U.S. market,” said Michael W. Heslop, President of Blue Earth Diagnostics Inc. “We are very pleased to be in Massachusetts and we look forward to being an active and productive member of the Burlington and Massachusetts business communities.”
Michael W. Heslop, President, Blue Earth Diagnostics Inc.
Mr. Heslop is the President of Blue Earth Diagnostics Inc. and has more than 25 years of experience in commercial and general management with Glaxo Wellcome USA, Genzyme Corporation and, most recently, Lantheus Medical Imaging, where he was Vice President Business Development and Strategy. While at Genzyme, he held the positions of Senior Vice President & General Manager of the Biosurgery and Endocrine businesses, and Vice President, Global Marketing, PGH Business. Mr. Heslop received a B.Sc. degree in Biology from McGill University and an M.B.A. from Concordia University.
Peter Gardiner, MB ChB, MRCP, FFPM, Vice President, Medical Affairs
Dr. Gardiner is responsible for the medical and scientific support of all commercial activities in the United States. His more than 30 years of industry experience has included clinical research and medical affairs roles of increasing responsibility with GD Searle, Gensia, DuPont Pharmaceuticals, Bristol-Myers Squibb, BG Medicine and Navidea Biopharmaceuticals. A graduate of Leeds University Medical School, Dr. Gardiner is a Member of the Royal College of Physicians and a Fellow of its Faculty of Pharmaceutical Medicine.
Bradley K. Pounds, Vice President, Sales U.S.
Mr. Pounds has more than 30 years of experience in diagnostic imaging, including radiopharmaceuticals and contrast agents used for ultrasound and magnetic resonance imaging. He has led multifunctional teams in marketing, medical affairs and sales for both large and small pharmaceutical companies, including Lantheus Medical Imaging, Lilly USA and Navidea Biopharmaceuticals. Mr. Pounds has a Bachelor of Science degree from the University of Houston.
David Pendleton, Vice President, Marketing
Mr. Pendleton has more than 30 years of experience in diagnostic imaging and radiopharmaceuticals and has held numerous commercial leadership positions in marketing, sales and business development, including executive positions at New England Nuclear, DuPont Medical Imaging, Bristol-Myers Squibb, Theseus Imaging, inVentiv Health, Lantheus Medical Imaging and Navidea Biopharmaceuticals. He has consulted for a variety of companies across numerous therapeutic specialties. Mr. Pendleton has a Bachelor of Science degree from Northeastern University.
Christa Dhimo, Vice President, Strategy & Execution U.S.
Ms. Dhimo has more than 20 years of experience in setting and executing global growth and performance strategies. She has led many initiatives across various industries in companies both large and small such as Fidelity Investments, Salary.com (an IBM Company), Raytheon, and, most recently, Lantheus Medical Imaging where she was the Senior Director of Strategic Programs. Ms. Dhimo is a PMP® and received a BA from the University of Massachusetts, an MBA from Northeastern University and a Master in Management - Informatics from the University of Dallas. She also holds a Master Certificate in Strategic Organizational Leadership from Villanova University.
Priscilla Harlan, Vice President, Corporate Communications
Ms. Harlan has more than 25 years of communications experience in the life sciences industry, including executive positions at Lantheus Medical Imaging, Molecular Insight Pharmaceuticals and Sepracor (now Sunovion) and agency leadership positions at Feinstein Kean Healthcare (Ogilvy) and Complete Healthcare Communications. She has consulted to companies across a spectrum of therapeutic areas. Ms. Harlan has a Bachelor of Arts degree in Biology and History from the University of North Carolina.
“We are very pleased to be in Massachusetts and we look forward to being an active and productive member of the Burlington and Massachusetts business communities.”
Tweet this
“A strong presence in the United States is a critical next step in Blue Earth’s mission to deliver new molecular imaging agents to cancer patients with unmet medical needs,” said Jonathan Allis, D.Phil., CEO of Blue Earth Diagnostics Ltd. “With our lead PET imaging product candidate, fluciclovine F 18, in Priority Review with the U.S. Food and Drug Administration, we need to plan for its potential approval and for future growth. Mike Heslop has been leading the U.S. team as President of Blue Earth Diagnostics Inc. With his leadership and that of the other proven industry leaders who have recently joined the Company, we believe we are well-positioned for success and we are excited about the future.”
“Blue Earth’s headquarters in Massachusetts will provide sales, marketing and medical affairs support for the development and commercialization of fluciclovine F 18 in the important U.S. market,” said Michael W. Heslop, President of Blue Earth Diagnostics Inc. “We are very pleased to be in Massachusetts and we look forward to being an active and productive member of the Burlington and Massachusetts business communities.”
Michael W. Heslop, President, Blue Earth Diagnostics Inc.
Mr. Heslop is the President of Blue Earth Diagnostics Inc. and has more than 25 years of experience in commercial and general management with Glaxo Wellcome USA, Genzyme Corporation and, most recently, Lantheus Medical Imaging, where he was Vice President Business Development and Strategy. While at Genzyme, he held the positions of Senior Vice President & General Manager of the Biosurgery and Endocrine businesses, and Vice President, Global Marketing, PGH Business. Mr. Heslop received a B.Sc. degree in Biology from McGill University and an M.B.A. from Concordia University.
Peter Gardiner, MB ChB, MRCP, FFPM, Vice President, Medical Affairs
Dr. Gardiner is responsible for the medical and scientific support of all commercial activities in the United States. His more than 30 years of industry experience has included clinical research and medical affairs roles of increasing responsibility with GD Searle, Gensia, DuPont Pharmaceuticals, Bristol-Myers Squibb, BG Medicine and Navidea Biopharmaceuticals. A graduate of Leeds University Medical School, Dr. Gardiner is a Member of the Royal College of Physicians and a Fellow of its Faculty of Pharmaceutical Medicine.
Bradley K. Pounds, Vice President, Sales U.S.
Mr. Pounds has more than 30 years of experience in diagnostic imaging, including radiopharmaceuticals and contrast agents used for ultrasound and magnetic resonance imaging. He has led multifunctional teams in marketing, medical affairs and sales for both large and small pharmaceutical companies, including Lantheus Medical Imaging, Lilly USA and Navidea Biopharmaceuticals. Mr. Pounds has a Bachelor of Science degree from the University of Houston.
David Pendleton, Vice President, Marketing
Mr. Pendleton has more than 30 years of experience in diagnostic imaging and radiopharmaceuticals and has held numerous commercial leadership positions in marketing, sales and business development, including executive positions at New England Nuclear, DuPont Medical Imaging, Bristol-Myers Squibb, Theseus Imaging, inVentiv Health, Lantheus Medical Imaging and Navidea Biopharmaceuticals. He has consulted for a variety of companies across numerous therapeutic specialties. Mr. Pendleton has a Bachelor of Science degree from Northeastern University.
Christa Dhimo, Vice President, Strategy & Execution U.S.
Ms. Dhimo has more than 20 years of experience in setting and executing global growth and performance strategies. She has led many initiatives across various industries in companies both large and small such as Fidelity Investments, Salary.com (an IBM Company), Raytheon, and, most recently, Lantheus Medical Imaging where she was the Senior Director of Strategic Programs. Ms. Dhimo is a PMP® and received a BA from the University of Massachusetts, an MBA from Northeastern University and a Master in Management - Informatics from the University of Dallas. She also holds a Master Certificate in Strategic Organizational Leadership from Villanova University.
Priscilla Harlan, Vice President, Corporate Communications
Ms. Harlan has more than 25 years of communications experience in the life sciences industry, including executive positions at Lantheus Medical Imaging, Molecular Insight Pharmaceuticals and Sepracor (now Sunovion) and agency leadership positions at Feinstein Kean Healthcare (Ogilvy) and Complete Healthcare Communications. She has consulted to companies across a spectrum of therapeutic areas. Ms. Harlan has a Bachelor of Arts degree in Biology and History from the University of North Carolina.